Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979326306> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- W2979326306 endingPage "vi119" @default.
- W2979326306 startingPage "vi119" @default.
- W2979326306 abstract "Abstract Background Retrospective analysis of randomized control trials suggested that right-sided tumors derive less benefit from addition of anti-epidermal growth factor receptor antibodies(anti-EGFRs) to chemotherapy as first-line therapy . Furthermore, other retrospective studies suggest that anti-EGFRs as second or later line treatment also derive less benefit in right-sided tumors compared with left-sided tumors, although there is no definitive Conclusion. Patients and Methods Patients with KRAS and RAS wild type mCRC who were treated with anti-EGFRs as second or later line treatment from 2008 to 2018 at Kameda Medical Center were included in the study. We retrospectively analyzed the difference in efficacy of anti-EGFRs according to the location of primary tumor. Results Among 69 of patients, 49 and 20 had right- and left-sided tumors, respectively. Thirty-six patients treated with chemotherapy plus anti-EGFRs (treatment A), 33 patients treated with anti-EGFRs alone (treatment B). Median overall survival was 33 month in left-sided tumors versus 22 month in right-sided tumors. Overall response rate(ORR), disease control rate(DCR), and median progression free survival(PFS) were 22%, 29% and 4.0 months in left-sided tumor and 0%, 10% and 2.5 months in right-sided tumors, respectively.(p = 0.017) Overall response rate(ORR), disease control rate(DCR), the and median progression free survival(PFS) were 9%, 40% and 4.0 months in left-sided tumor and 0%, 9% and 1 months in right-sided tumors, respectively.(p = 0.017) Conclusion Compared with left-sided tumors, right-sided tumors responded less to anti-EGFRs and had poor prognosis." @default.
- W2979326306 created "2019-10-18" @default.
- W2979326306 creator A5004647173 @default.
- W2979326306 creator A5011462047 @default.
- W2979326306 creator A5038119341 @default.
- W2979326306 creator A5058647420 @default.
- W2979326306 creator A5082695210 @default.
- W2979326306 creator A5084391122 @default.
- W2979326306 date "2019-10-01" @default.
- W2979326306 modified "2023-10-18" @default.
- W2979326306 title "Primary tumor location and benefit of anti-EGFRs as second or later line treatment in RAS-RAS wild type mCRC patients" @default.
- W2979326306 doi "https://doi.org/10.1093/annonc/mdz343.004" @default.
- W2979326306 hasPublicationYear "2019" @default.
- W2979326306 type Work @default.
- W2979326306 sameAs 2979326306 @default.
- W2979326306 citedByCount "0" @default.
- W2979326306 crossrefType "journal-article" @default.
- W2979326306 hasAuthorship W2979326306A5004647173 @default.
- W2979326306 hasAuthorship W2979326306A5011462047 @default.
- W2979326306 hasAuthorship W2979326306A5038119341 @default.
- W2979326306 hasAuthorship W2979326306A5058647420 @default.
- W2979326306 hasAuthorship W2979326306A5082695210 @default.
- W2979326306 hasAuthorship W2979326306A5084391122 @default.
- W2979326306 hasBestOaLocation W29793263061 @default.
- W2979326306 hasConcept C126322002 @default.
- W2979326306 hasConcept C143998085 @default.
- W2979326306 hasConcept C502942594 @default.
- W2979326306 hasConcept C71924100 @default.
- W2979326306 hasConceptScore W2979326306C126322002 @default.
- W2979326306 hasConceptScore W2979326306C143998085 @default.
- W2979326306 hasConceptScore W2979326306C502942594 @default.
- W2979326306 hasConceptScore W2979326306C71924100 @default.
- W2979326306 hasLocation W29793263061 @default.
- W2979326306 hasOpenAccess W2979326306 @default.
- W2979326306 hasPrimaryLocation W29793263061 @default.
- W2979326306 hasRelatedWork W1506200166 @default.
- W2979326306 hasRelatedWork W1995515455 @default.
- W2979326306 hasRelatedWork W2039318446 @default.
- W2979326306 hasRelatedWork W2048182022 @default.
- W2979326306 hasRelatedWork W2080531066 @default.
- W2979326306 hasRelatedWork W2604872355 @default.
- W2979326306 hasRelatedWork W2748952813 @default.
- W2979326306 hasRelatedWork W2899084033 @default.
- W2979326306 hasRelatedWork W3032375762 @default.
- W2979326306 hasRelatedWork W3108674512 @default.
- W2979326306 hasVolume "30" @default.
- W2979326306 isParatext "false" @default.
- W2979326306 isRetracted "false" @default.
- W2979326306 magId "2979326306" @default.
- W2979326306 workType "article" @default.